Cryo-Cell International (CCEL)
Market Price (3/15/2026): $2.92 | Market Cap: $23.5 MilSector: Health Care | Industry: Health Care Facilities
Cryo-Cell International (CCEL)
Market Price (3/15/2026): $2.92Market Cap: $23.5 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% | Weak multi-year price returns2Y Excs Rtn is -79%, 3Y Excs Rtn is -88% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.3%, Rev Chg QQuarterly Revenue Change % is -2.3% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -37% | Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. | |
| Attractive yieldDividend Yield is 14%, FCF Yield is 22% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -37% |
| Attractive yieldDividend Yield is 14%, FCF Yield is 22% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -79%, 3Y Excs Rtn is -88% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.3%, Rev Chg QQuarterly Revenue Change % is -2.3% |
| Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. NYSE American Listing Non-Compliance: Cryo-Cell International received a notice on March 9, 2026, from NYSE American stating non-compliance with continued listing standards. This was primarily due to reporting a stockholders' deficit as of November 30, 2025, and incurring net losses in two of its three most recent fiscal years, specifically ending November 30, 2023, 2024, and 2025. This notification creates uncertainty and the risk of potential delisting if the company fails to regain compliance within an allotted 18-month period, negatively impacting investor confidence.
2. Significant Net Losses for Fiscal Year 2025: The company reported a consolidated net loss of $2.4 million for the fiscal year ended November 30, 2025, representing a substantial decline of 704.2% compared to the previous fiscal year. Additionally, Cryo-Cell International reported a Q4 2025 loss of $3.82 million, or -$0.47 earnings per share (EPS), a significant decrease of 609.4% from the prior quarter. This sustained unprofitability and substantial quarterly loss signal underlying operational challenges and poor financial health.
Show more
Stock Movement Drivers
Fundamental Drivers
The -32.1% change in CCEL stock from 11/30/2025 to 3/14/2026 was primarily driven by a -31.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.30 | 2.92 | -32.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 32 | -0.6% |
| P/S Multiple | 1.1 | 0.7 | -31.7% |
| Shares Outstanding (Mil) | 8 | 8 | 0.0% |
| Cumulative Contribution | -32.1% |
Market Drivers
11/30/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| CCEL | -32.1% | |
| Market (SPY) | -3.1% | 3.4% |
| Sector (XLV) | -5.0% | -16.9% |
Fundamental Drivers
The -37.9% change in CCEL stock from 8/31/2025 to 3/14/2026 was primarily driven by a -37.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.70 | 2.92 | -37.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 32 | -1.3% |
| P/S Multiple | 1.2 | 0.7 | -37.2% |
| Shares Outstanding (Mil) | 8 | 8 | 0.3% |
| Cumulative Contribution | -37.9% |
Market Drivers
8/31/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| CCEL | -37.9% | |
| Market (SPY) | 3.0% | 13.5% |
| Sector (XLV) | 9.5% | 4.3% |
Fundamental Drivers
The -61.9% change in CCEL stock from 2/28/2025 to 3/14/2026 was primarily driven by a -61.5% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.67 | 2.92 | -61.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 32 | -1.3% |
| P/S Multiple | 1.9 | 0.7 | -61.5% |
| Shares Outstanding (Mil) | 8 | 8 | 0.1% |
| Cumulative Contribution | -61.9% |
Market Drivers
2/28/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| CCEL | -61.9% | |
| Market (SPY) | 12.4% | 6.7% |
| Sector (XLV) | 1.9% | 8.1% |
Fundamental Drivers
The -16.3% change in CCEL stock from 2/28/2023 to 3/14/2026 was primarily driven by a -23.9% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.49 | 2.92 | -16.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 32 | 4.1% |
| P/S Multiple | 1.0 | 0.7 | -23.9% |
| Shares Outstanding (Mil) | 9 | 8 | 5.7% |
| Cumulative Contribution | -16.3% |
Market Drivers
2/28/2023 to 3/14/2026| Return | Correlation | |
|---|---|---|
| CCEL | -16.3% | |
| Market (SPY) | 73.4% | 5.1% |
| Sector (XLV) | 23.3% | 4.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCEL Return | 84% | -64% | 36% | 33% | -51% | -8% | -45% |
| Peers Return | 6% | -42% | -9% | -0% | -14% | -5% | -55% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| CCEL Win Rate | 25% | 8% | 42% | 42% | 33% | 33% | |
| Peers Win Rate | 52% | 42% | 44% | 50% | 46% | 25% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CCEL Max Drawdown | 0% | -64% | -30% | -15% | -51% | -8% | |
| Peers Max Drawdown | -24% | -56% | -38% | -23% | -36% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RVTY, CYRX, VCEL, PLUR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | CCEL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -79.0% | -25.4% |
| % Gain to Breakeven | 376.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -26.3% | -33.9% |
| % Gain to Breakeven | 35.6% | 51.3% |
| Time to Breakeven | 531 days | 148 days |
| 2018 Correction | ||
| % Loss | -19.9% | -19.8% |
| % Gain to Breakeven | 24.8% | 24.7% |
| Time to Breakeven | 609 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -83.0% | -56.8% |
| % Gain to Breakeven | 487.5% | 131.3% |
| Time to Breakeven | 750 days | 1,480 days |
Compare to RVTY, CYRX, VCEL, PLUR
In The Past
Cryo-Cell International's stock fell -79.0% during the 2022 Inflation Shock from a high on 9/2/2021. A -79.0% loss requires a 376.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cryo-Cell International (CCEL)
AI Analysis | Feedback
Here are 1-2 brief analogies for Cryo-Cell International (CCEL):
- It's like Fidelity Investments, but instead of managing your child's financial future, they preserve their stem cells for future health.
- It's like Iron Mountain, but for human stem cells, providing long-term cryogenic storage of umbilical cord blood and tissue.
AI Analysis | Feedback
- Cord Blood Banking: A service focused on the collection, processing, and cryogenic storage of umbilical cord blood stem cells for potential future family use.
- Cord Tissue Banking: A service for storing a section of the umbilical cord tissue, a source of mesenchymal stem cells used in regenerative medicine.
- PrepaCyte CB processing system: A proprietary technology manufactured and sold by the company, used for processing umbilical cord blood stem cells.
AI Analysis | Feedback
Cryo-Cell International (CCEL) primarily serves individuals, specifically expectant parents and families, for its core cord blood and cord tissue stem cell storage services. However, it also serves other categories related to its business model and product offerings.
The major customer categories that Cryo-Cell International serves are:
- Expectant Parents and Families: These are the primary direct consumers who purchase the cord blood and cord tissue stem cell preservation and cryogenic storage services for their family's potential future medical use in regenerative medicine or other therapeutic applications.
- Healthcare Professionals and Childbirth Educators: While not direct paying customers for the storage services, this group includes obstetricians, pediatricians, certified nurse-midwives, and childbirth educators. Cryo-Cell International markets to and distributes information through these professionals, who serve as crucial informational channels and influencers for expectant parents considering stem cell preservation.
- Other Cellular Processing Facilities, Research Institutions, and Cord Blood Banks: These entities represent business-to-business customers who purchase the PrepaCyte CB processing system, a proprietary technology manufactured and sold by Cryo-Cell International for processing umbilical cord blood stem cells.
AI Analysis | Feedback
null
AI Analysis | Feedback
David I. Portnoy Co-Chief Executive Officer
Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of Cryo-Cell International since August 2011. Since 2002, he has also served as Chairman of the Board of Directors of Partner Community, Inc., which facilitates B2B integrations for telecommunication service providers. His venture capital company led early-stage investment rounds in Waves Audio Ltd, a leading developer of audio plugins and signal processors. Mr. Portnoy has been engaged in managing his personal investments since April 1997. He graduated Magna Cum Laude from The Wharton School of Finance at the University of Pennsylvania in 1984.
Mark L. Portnoy Co-Chief Executive Officer
Mr. Portnoy has served as a Director and Co-Chief Executive Officer of Cryo-Cell International since August 2011. He has been instrumental in expanding the company's core business units, including leading the establishment of a national sales force in 2012, the adoption and acquisition of exclusive worldwide rights to the PrepaCyte-CB processing system, and the purchase of Cord:Use Cord Blood Bank. Since 2002 and 2007, he has also served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., respectively.
Jill Taymans Chief Financial Officer
Ms. Taymans has served as Cryo-Cell International's Chief Financial Officer since 1998. Prior to joining the company, she served for three years as Controller for a telecommunications company. Ms. Taymans has over 30 years of experience as an accountant in both the public and private sectors. She graduated from the University of Maryland in 1991 with a BS in Accounting.
Oleg Mikulinsky Chief Information Officer
Mr. Mikulinsky has served as Cryo-Cell International's Chief Information Officer since March 2012. He is a software technologist and serial entrepreneur, having been a founding member of several software enterprises. He previously served as Chief Technology Officer of Partner-Community, Inc. and Chief Technology Officer at uTIPu Inc. from 2007 to 2009. Mr. Mikulinsky also served as the Director of Enterprise Architecture at WebLayers, Inc.
Joanne Kurtzberg, M.D. Medical Director
Dr. Kurtzberg is the Medical Director of Cryo-Cell International. She is recognized as a pioneer in the cord blood field, having performed the first unrelated cord blood stem cell transplant in 1993. Dr. Kurtzberg is an internationally renowned expert in pediatric hematology-oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and the novel application of cord blood in cellular therapy and regenerative medicine. She is the Director of the Marcus Center for Cellular Cures at the Duke University School of Medicine and is President of the Cord Blood Association.
AI Analysis | Feedback
The key risks to Cryo-Cell International's business include the risk of NYSE American delisting, uncertainty from the Duke arbitration, and reliance on the evolving landscape of stem cell therapies amidst intense market competition.
The most significant risk is the potential for **NYSE American delisting and associated financial instability**. Cryo-Cell International has received a notice from NYSE American indicating non-compliance with continued listing standards, specifically due to a stockholders' deficit and net losses in recent fiscal years. Failure to regain compliance could lead to the delisting of its common stock, which would likely depress the stock price, severely limit liquidity, and restrict the company's ability to raise additional capital.
Another major risk is the **uncertainty and potential negative impact stemming from the Duke arbitration**. An ongoing dispute with Duke University over the Duke License Agreement introduces significant uncertainty, with potential negative impacts on Cryo-Cell International's business and financial position. The outcome of this arbitration is unpredictable, and there is a risk of not recouping damages or investments related to the agreement. This dispute has also reportedly halted investments in related activities and delayed the opening of the Cryo-Cell Institute for Cellular Therapies.
Finally, Cryo-Cell International faces risks associated with its **reliance on the evolving landscape of stem cell therapies and intense market competition**. The success and long-term viability of the company's core service—the collection and preservation of umbilical cord blood and tissue stem cells—are heavily dependent on the widespread market acceptance and continued advancements in regenerative medicine and stem cell therapeutic applications. The stem cell preservation market is increasingly competitive, with approximately 25 other national private cord blood banks, some potentially possessing greater financial resources, which can lead to pricing pressures and challenges in customer acquisition.
AI Analysis | Feedback
The clear emerging threat to Cryo-Cell International is the advancement and increasing therapeutic utility of induced pluripotent stem cell (iPSC) technology.
iPSC technology allows adult somatic cells (e.g., skin cells) to be reprogrammed into a pluripotent state, meaning they can differentiate into any cell type in the body. As this technology matures and becomes more readily available, efficient, and cost-effective, it could significantly diminish the value proposition of banking umbilical cord blood and tissue at birth for future therapeutic use. If individuals can generate patient-specific pluripotent stem cells from their own adult cells at any point in their lives, the need for long-term cryopreservation of perinatal stem cells for "family use" may decrease, thereby threatening Cryo-Cell International's core business model.
AI Analysis | Feedback
Here are the addressable market sizes for Cryo-Cell International's main products and services:Umbilical Cord Blood Stem Cells and Cord Tissue Preservation (Family Use)
The global addressable market for cord blood banking services, which encompasses both umbilical cord blood and cord tissue storage for family use, was estimated at US$33.9 billion in 2023. This market is projected to grow to US$65.36 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 6.15% from 2024 to 2034. For the U.S. region, the cord blood banking services market was valued at USD 6.83 billion in 2022. It is expected to grow at a CAGR of 11.56% from 2023 to 2030, reaching an estimated USD 16.59 billion by 2030. North America, overall, held a significant share of the global cord blood banking services market, accounting for 42.5% in 2023 and 42% in 2024.PrepaCyte CB Processing System
nullAI Analysis | Feedback
Cryo-Cell International (CCEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends: 1. **Expansion into Cellular Therapy Commercialization via Infusion Clinics:** Cryo-Cell International anticipates establishing infusion clinics to administer treatments for conditions such as autism, cerebral palsy, and traumatic brain injuries. This expansion is facilitated by an exclusive license agreement with Duke University, which grants Cryo-Cell rights to intellectual property, proprietary processes, and clinical data related to cord blood and cord tissue stem cells through the FDA's Expanded Access Program. Other clinical indications currently under study, such as adult stroke, multiple sclerosis, osteoarthritis, and COVID-19, are also included in this license. An aspirational projection from a 2021 investor presentation indicated that the first infusion clinic could aim for annual revenues of $24 million. 2. **Growth in Biopharmaceutical Manufacturing and Specialized Biostorage Services:** The company plans to broaden its business segments to encompass biopharmaceutical manufacturing. Furthermore, Cryo-Cell launched its ExtraVault digital platform in March 2022, specifically designed to offer high-quality and cost-effective biostorage solutions for biopharmaceutical clients. This strategic move aims to capture revenue from the growing biopharma sector. 3. **Leveraging the Expanding Regenerative Medicine Market for Core Storage Services:** As the world's first private cord blood bank with a significant global client base, Cryo-Cell International is positioned to benefit from the projected substantial growth in the broader cell therapy processing market. This market is driven by increasing demand for regenerative medicine, expanding clinical and commercial activities in cell and gene therapy, and rising investments in research. The overall market growth is expected to create a tailwind for Cryo-Cell's core cord blood and cord tissue stem cell storage services, potentially leading to an increase in new customers and sustained demand.AI Analysis | Feedback
Share Repurchases
- Cryo-Cell International repurchased $169,502 of its common stock in fiscal year 2025.
Share Issuance
- Information regarding significant share issuances by the company for cash over the last 3-5 years was not readily available in the provided search results.
Inbound Investments
- Cryo-Cell International entered into a Credit Agreement with Susser Bank, which provides for a revolving credit facility and a term loan facility.
Outbound Investments
- In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University, granting the company rights to intellectual property, proprietary processes, and regulatory/clinical data related to cord blood and cord tissue.
- The company acquired assets from Cord:Use Cord Blood Bank, Inc., which enhanced its public cord blood inventory.
- Cryo-Cell purchased a 56,000 square-foot facility in Durham, North Carolina, to expand its cryopreservation and cold storage business.
Capital Expenditures
- The company acquired a 56,000 square-foot facility in Durham, North Carolina, to expand its cryopreservation and cold storage capabilities.
- Planned capital expenditures for the Cryo-Cell Institute for Cellular Therapies, which aimed to support biopharmaceutical manufacturing and clinic operations, have been halted due to a dispute with Duke University.
- Cryo-Cell anticipates that its current cash, marketable securities, and operating cash flows will cover known needs for the next 12 months, but additional capital may be required for future clinical trials and biopharmaceutical manufacturing depending on the outcome of the Duke License Agreement arbitration.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Cryo-Cell International Earnings Notes | 12/16/2025 | |
| Can Cryo-Cell International Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CCEL.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.82 |
| Mkt Cap | 0.4 |
| Rev LTM | 176 |
| Op Inc LTM | 5 |
| FCF LTM | 5 |
| FCF 3Y Avg | 3 |
| CFO LTM | 5 |
| CFO 3Y Avg | 7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.4% |
| Rev Chg 3Y Avg | 1.4% |
| Rev Chg Q | 7.0% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | 4.0% |
| Op Mgn 3Y Avg | 0.9% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 17.4% |
| CFO/Rev 3Y Avg | 15.5% |
| FCF/Rev LTM | 9.0% |
| FCF/Rev 3Y Avg | 3.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 3.4 |
| P/EBIT | -1.2 |
| P/E | 5.2 |
| P/CFO | 4.3 |
| Total Yield | 2.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.5% |
| D/E | 0.5 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.1% |
| 3M Rtn | -14.8% |
| 6M Rtn | -9.5% |
| 12M Rtn | -26.4% |
| 3Y Rtn | -29.6% |
| 1M Excs Rtn | -6.9% |
| 3M Excs Rtn | -15.7% |
| 6M Excs Rtn | -20.3% |
| 12M Excs Rtn | -48.6% |
| 3Y Excs Rtn | -100.3% |
Price Behavior
| Market Price | $2.92 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -54.3% | |
| 50 Days | 200 Days | |
| DMA Price | $3.37 | $4.28 |
| DMA Trend | down | down |
| Distance from DMA | -13.3% | -31.8% |
| 3M | 1YR | |
| Volatility | 26.8% | 52.0% |
| Downside Capture | 87.26 | 72.98 |
| Upside Capture | -78.30 | -21.66 |
| Correlation (SPY) | 5.5% | 0.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.22 | 0.02 | 0.15 | 0.47 | 0.18 | 0.22 |
| Up Beta | -0.01 | 0.25 | 0.67 | 1.86 | 0.12 | -0.03 |
| Down Beta | -1.77 | -0.53 | 0.39 | 0.03 | -0.12 | 0.50 |
| Up Capture | 13% | 10% | -77% | -19% | -2% | 6% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 11 | 19 | 27 | 56 | 113 | 350 |
| Down Capture | 23% | 34% | 66% | 78% | 97% | 52% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 20 | 32 | 63 | 131 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -51.3% | 51.8% | -1.21 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 6.8% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 0.5% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | 9.4% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | 0.4% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 11.5% |
| Bitcoin (BTCUSD) | -15.3% | 44.2% | -0.25 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -21.8% | 65.6% | -0.16 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 1.8% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 3.3% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | 1.7% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 4.1% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 5.2% |
| Bitcoin (BTCUSD) | 6.3% | 56.7% | 0.33 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -10.7% | 64.5% | -0.10 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 3.5% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 5.5% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | 2.3% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 4.8% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 7.6% |
| Bitcoin (BTCUSD) | 67.4% | 66.8% | 1.07 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/17/2024 | 2.5% | 0.2% | 40.2% |
| 2/24/2022 | -0.1% | -1.5% | -6.9% |
| 10/15/2021 | -3.5% | -4.2% | -5.8% |
| 7/19/2021 | 0.0% | 0.0% | 0.0% |
| 2/25/2021 | 0.0% | 0.0% | 0.0% |
| 10/19/2020 | 0.0% | 0.0% | 0.0% |
| 7/13/2020 | 0.0% | 0.0% | 0.0% |
| 3/2/2020 | 0.0% | -0.3% | -11.3% |
| SUMMARY STATS | |||
| # Positive | 6 | 5 | 5 |
| # Negative | 2 | 3 | 3 |
| Median Positive | 0.0% | 0.0% | 0.0% |
| Median Negative | -1.8% | -1.5% | -6.9% |
| Max Positive | 2.5% | 0.2% | 40.2% |
| Max Negative | -3.5% | -4.2% | -11.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 11/30/2025 | 02/27/2026 | 10-K |
| 08/31/2025 | 10/15/2025 | 10-Q |
| 05/31/2025 | 07/15/2025 | 10-Q |
| 02/28/2025 | 04/14/2025 | 10-Q |
| 11/30/2024 | 02/28/2025 | 10-K |
| 08/31/2024 | 10/15/2024 | 10-Q |
| 05/31/2024 | 07/15/2024 | 10-Q |
| 02/29/2024 | 04/15/2024 | 10-Q |
| 11/30/2023 | 02/28/2024 | 10-K |
| 08/31/2023 | 10/12/2023 | 10-Q |
| 05/31/2023 | 07/14/2023 | 10-Q |
| 02/28/2023 | 04/21/2023 | 10-Q |
| 11/30/2022 | 02/28/2023 | 10-K |
| 08/31/2022 | 10/18/2022 | 10-Q |
| 05/31/2022 | 07/11/2022 | 10-Q |
| 02/28/2022 | 04/13/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 6,449 | 28,763 | 3,649,926 | Form |
| 2 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.43 | 5,564 | 24,649 | 3,650,023 | Form |
| 3 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 3,411 | 15,213 | 3,689,954 | Form |
| 4 | Portnoy, David | Chairman, Co-CEO | Corporation | Buy | 9182025 | 4.49 | 1,751 | 7,862 | 726,630 | Form |
| 5 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 9102025 | 4.31 | 5,271 | 22,718 | 1,090,551 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.